In this large cohort of 240 MM cases treated with proteasome inhibitors or immunomodulators, an inferior overall response rate (ORR) was reported for patients with elevated CD68-positive and CD163-positive TAM [81]. The gene discussed is CD163; the disease is Miyoshi myopathy.